These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9391160)

  • 1. Molecular determinants of tissue selectivity in estrogen receptor modulators.
    Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
    Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
    J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
    Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
    J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
    Sato M; Rippy MK; Bryant HU
    FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site.
    Weatherman RV; Carroll DC; Scanlan TS
    Bioorg Med Chem Lett; 2001 Dec; 11(24):3129-31. PubMed ID: 11720858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
    J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
    Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB
    Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
    Sömjen D; Waisman A; Kaye AM
    J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
    Dodge JA; Lugar CW; Cho S; Short LL; Sato M; Yang NN; Spangle LA; Martin MJ; Phillips DL; Glasebrook AL; Osborne JJ; Frolik CA; Bryant HU
    J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):97-106. PubMed ID: 9328215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.
    Paech K; Webb P; Kuiper GG; Nilsson S; Gustafsson J; Kushner PJ; Scanlan TS
    Science; 1997 Sep; 277(5331):1508-10. PubMed ID: 9278514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
    Bryant HU; Dere WH
    Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.
    Jones CD; Jevnikar MG; Pike AJ; Peters MK; Black LJ; Thompson AR; Falcone JF; Clemens JA
    J Med Chem; 1984 Aug; 27(8):1057-66. PubMed ID: 6431104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
    Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
    Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An estrogen receptor basis for raloxifene action in bone.
    Bryant HU; Glasebrook AL; Yang NN; Sato M
    J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.
    Barkhem T; Andersson-Ross C; Höglund M; Nilsson S
    J Steroid Biochem Mol Biol; 1997 May; 62(1):53-64. PubMed ID: 9366498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.
    Greschik H; Flaig R; Renaud JP; Moras D
    J Biol Chem; 2004 Aug; 279(32):33639-46. PubMed ID: 15161930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of raloxifene hydrochloride in women.
    Khovidhunkit W; Shoback DM
    Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha.
    Dayan G; Lupien M; Auger A; Anghel SI; Rocha W; Croisetière S; Katzenellenbogen JA; Mader S
    Mol Pharmacol; 2006 Aug; 70(2):579-88. PubMed ID: 16679488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multiplexed screening method for agonists and antagonists of the estrogen receptor protein.
    Li Z; Yan M; Li Z; Vuki M; Wu D; Liu F; Zhong W; Zhang L; Xu D
    Anal Bioanal Chem; 2012 May; 403(5):1373-84. PubMed ID: 22453607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.